Mr. Makov is the former President & CEO of Teva Pharmaceutical Industries Ltd (2002-2007). He is among Israel’s most respected corporate leaders and is widely credited with making Teva the world’s leader of generic pharmaceuticals. Mr. Makov led Teva through an aggressive M&A strategy, leading record breaking acquisitions of: Biogal (1995), Novopharm (1999), Sicor (2004) and IVAX (2006). During Makov’s tenure as CEO, the company’s sales increased over four-fold, to approximately $8.5 billion, and its adjusted net income increased approximately six-fold, to over $1.8 billion.
Prior to joining Teva, Mr. Makov led a number of companies in various industries, and founded Israel’s first biotech company, Interpharm, which later went public in the US. Mr. Makov is a member of the Board of Directors of the Israel National Nanotechnology Initiative, an initiative he also helped establish. He is a member of the Executive Board & Management Committee of the Weizmann Institute of Science and the Chairman of the Board of the Institute for Policy and Strategy at the Interdisciplinary Center of Herzliya. Israel Makov holds a B.Sc. in Agriculture and M. Sc in Economics from the Hebrew University in Jerusalem.
.
Suzana Nahum-Zilberberg
Mrs. Suzana Nahum-Zilberberg is the CEO of BioLight. Previously Mrs. Nahum-Zilberberg worked at Teva Pharmaceuticals Industries Ltd for 12 years in several positions, her last role being Vice President Asia and Pacific, leading the penetration of Teva into Japan and China. In her position Mrs. Nahum-Zilberberg led the JV agreement with Kowa Pharmaceutical in 2008 and the acquisition of Taisho Pharmaceutical in 2009, leading Teva to become the fifth largest generic company in Japan.
Mrs. Nahum-Zilberberg holds a BA in Accounting and Economics from Tel Aviv University, MBA in Finance and Marketing from Tel Aviv University and is certified CPA.
